Trial · NCT02424539
Results by group297
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 297
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline in Daily, Reflective Total Nasal Symptom Scores (rTNSS) Over the First 2 Weeks Treatment Period | Placebo | -1.95 | Standard Error 0.16 | Scores on a scale | |
| Mean Change From Baseline in Daily, Reflective Total Nasal Symptom Scores (rTNSS) Over the First 2 Weeks Treatment Period | FF 55 µg QD | -3.18 | Standard Error 0.16 | Scores on a scale | |
| Mean Change From Baseline in Daily, Reflective Total Nasal Symptom Scores (rTNSS) Over the First 2 Weeks Treatment Period | FF 110 µg QD | -3.28 | Standard Error 0.16 | Scores on a scale | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | Placebo | Significantly improved | 13 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | FF 55 µg QD | Significantly improved | 38 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | FF 110 µg QD | Significantly improved | 51 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | Placebo | Moderately improved | 30 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | FF 55 µg QD | Moderately improved | 48 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | FF 110 µg QD | Moderately improved | 33 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | Placebo | Mildly improved | 45 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | FF 55 µg QD | Mildly improved | 22 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | FF 110 µg QD | Mildly improved | 29 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | Placebo | No change | 21 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | FF 55 µg QD | No change | 4 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | FF 110 µg QD | No change | 4 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | Placebo | Mildly worse | 3 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | FF 55 µg QD | Mildly worse | 1 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | FF 110 µg QD | Mildly worse | 1 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | Placebo | Moderately worse | 1 | Participants | |
| Number of Participants Showing Response to the Therapy After the First 2 Weeks Treatment on a 7-point Categorical Scale | FF 55 µg QD | Moderately worse | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02424539/results